ENXTBR:CYAD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of cancer.


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Celyad's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CYAD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

32.1%

CYAD

5.9%

BE Biotechs

4.6%

BE Market


1 Year Return

-36.8%

CYAD

72.1%

BE Biotechs

-18.2%

BE Market

Return vs Industry: CYAD underperformed the Belgian Biotechs industry which returned 63.7% over the past year.

Return vs Market: CYAD underperformed the Belgian Market which returned -18.4% over the past year.


Shareholder returns

CYADIndustryMarket
7 Day32.1%5.9%4.6%
30 Day27.6%44.3%6.5%
90 Day26.1%44.8%-8.6%
1 Year-36.8%-36.8%72.1%72.1%-17.2%-18.2%
3 Year-72.4%-72.4%390.5%390.5%-27.5%-31.7%
5 Year-83.0%-83.0%339.3%339.3%-22.9%-31.1%

Price Volatility Vs. Market

How volatile is Celyad's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Celyad undervalued compared to its fair value and its price relative to the market?

3.32x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CYAD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CYAD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CYAD is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CYAD is unprofitable, so we can't compare its PE Ratio to the Belgian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYAD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYAD is good value based on its PB Ratio (3.3x) compared to the BE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Celyad forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-14.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYAD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CYAD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CYAD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CYAD's revenue (28.4% per year) is forecast to grow faster than the Belgian market (3% per year).

High Growth Revenue: CYAD's revenue (28.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CYAD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Celyad performed over the past 5 years?

-12.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CYAD is currently unprofitable.

Growing Profit Margin: CYAD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CYAD is unprofitable, and losses have increased over the past 5 years at a rate of -12.3% per year.

Accelerating Growth: Unable to compare CYAD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYAD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.1%).


Return on Equity

High ROE: CYAD has a negative Return on Equity (-62.76%), as it is currently unprofitable.


Next Steps

Financial Health

How is Celyad's financial position?


Financial Position Analysis

Short Term Liabilities: CYAD's short term assets (€42.8M) exceed its short term liabilities (€11.9M).

Long Term Liabilities: CYAD's short term assets (€42.8M) exceed its long term liabilities (€32.3M).


Debt to Equity History and Analysis

Debt Level: CYAD's debt to equity ratio (0.5%) is considered satisfactory.

Reducing Debt: CYAD's debt to equity ratio has increased from 0% to 0.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYAD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CYAD has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 12.7% each year.


Next Steps

Dividend

What is Celyad's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CYAD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CYAD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYAD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYAD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CYAD's dividend in 3 years as they are not forecast to pay a notable one for the Belgian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Filippo Petti (43yo)

1.17yrs

Tenure

Mr. Filippo Joseph Petti serves as Director at Celyad SA since November 2019. He has been the Chief Executive Officer and Chief Financial Officer of Celyad SA since April 1, 2019. Mr. Petti served as the C ...


Leadership Team

NamePositionTenureCompensationOwnership
Michel E. Lussier
Co-Founder & Independent Chairman13.42yrs€85.00k1.15% 1.7m
Filippo Petti
CEO, CFO & Director1.17yrsno datano data
David Gilham
Chief Scientific Officer0.083yrno datano data
Nicolas Van Hoecke
Director of Investor Relations & Communications1.75yrsno datano data
Philippe Dechamps
Chief Legal Officer3.75yrsno datano data
Stephen Rubino
Chief Business Development Officer0.33yrno datano data
Philippe Nobels
Vice President of Human Resources3.67yrsno datano data
Frédéric Lehmann
Vice President of Clinical Development & Medical Affairs3.92yrsno datano data

1.8yrs

Average Tenure

54yo

Average Age

Experienced Management: CYAD's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Michel E. Lussier
Co-Founder & Independent Chairman13.42yrs€85.00k1.15% 1.7m
Filippo Petti
CEO, CFO & Director1.17yrsno datano data
Rudy DeKeyser
Independent Director13.42yrs€80.00kno data
Scott Antonia
Member of Scientific Advisory Board4.17yrsno datano data
Marc Ernstoff
Member of Scientific Advisory Board4.17yrsno datano data
Serge Goblet
Non-Executive Director12.42yrs€35.00k16.87% 25.5m
Hinrich Abken
Member of Scientific Advisory Board4.17yrsno datano data
Marco Davila
Member of Scientific Advisory Board4.17yrsno datano data
Stéphane Dépil
Member of Scientific Advisory Board4.17yrsno datano data
Sebastian Kobold
Member of Scientific Advisory Board4.17yrsno datano data

4.2yrs

Average Tenure

57yo

Average Age

Experienced Board: CYAD's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.7%.


Top Shareholders

Company Information

Celyad SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Celyad SA
  • Ticker: CYAD
  • Exchange: ENXTBR
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €151.414m
  • Shares outstanding: 13.94m
  • Website: https://www.celyad.com

Number of Employees


Location

  • Celyad SA
  • Axis Business Park
  • Rue Edouard Belin 2
  • Mont-Saint-Guibert
  • Walloon Brabant
  • 1435
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYADENXTBR (Euronext Brussels)YesOrdinary SharesBEEURJul 2013
CYADBBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJul 2013
0QFKLSE (London Stock Exchange)YesOrdinary SharesGBEURJul 2013
1C0DB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2013
CLYY.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2013
CYADNasdaqGM (Nasdaq Global Market)ADS EACH REPR 1 ORDUSUSDJun 2015
1C0SDB (Deutsche Boerse AG)ADS EACH REPR 1 ORDDEEURJun 2015

Biography

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of cancer. The company’s lead drug product candidates include CYAD-01 and CYAD-02 autologous cell therapies, which are in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. It is also developing CYAD-101, an allogeneic cell therapy that is in Phase I clinical trial for the treatment of metastatic colorectal cancer; and CYAD-103, an allogeneic CAR-T product candidate that is in preclinical development for the treatment of solid tumors. The company’s other preclinical candidates include CYAD-211, a CAR-T candidate targeting B-cell maturation antigen for the treatment of multiple myeloma; CYAD-221, a CAR-T candidate targeting CD19 for the treatment of B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting NKG2D and an undisclosed membrane protein. Celyad SA has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/02 23:43
End of Day Share Price2020/06/02 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.